NewsRoom Articles - BioMedWire (BMW)

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its…

ThursdayApr 16, 2026 10:00 am

New AI Tool Could Boost the Early Detection of Lung Cancer

Lung cancer is the leading cause of cancer-linked fatalities among men and women, and survival beyond five years post-diagnosis is minimal. This is largely because most cases are detected when they are already advanced. Scientists are therefore searching for ways to boost early detection so that treatment outcomes can improve and survival can increase. A new study seems to have found a way to use AI to improve the early detection of this disease. This tool could be especially helpful in flagging lung cancer when tumors are still small and are harder to detect using the existing diagnostic tools. These existing tools, such as CT scans, have…

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced…

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

WednesdayApr 15, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead. One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study. Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline. Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A…

TuesdayApr 14, 2026 10:00 am

Preclinical Study Reveals Promising Treatment for Glioblastoma

Glioblastoma is a deadly type of brain cancer which progresses rapidly and kills victims within months. For nearly two decades, no significant progress has been made in developing an effective treatment against this malignancy. Now, a new preclinical study using animal models has unveiled a potential breakthrough that could eliminate these tumors. The study, whose findings were published in the journal Nature, was conducted by scientists at the startup Trogenix. The team is made up of scientists at the Cancer Institute at University College London, the Royal Infirmary at Edinburgh, and the University of Edinburgh. The team developed SSEs technology (Synthetic Super-Enhancers) that entails using a viral vector to carry genetic instructions into glioblastoma tumors. The genetic instructions…

MondayApr 13, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World’s First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. Workplace substance misuse costs U.S. employers over $81 billion annually through lost productivity, accidents, healthcare costs, and liability, with studies indicating that up to 40% of industrial workplace fatalities involve alcohol misuse. MindBio is introducing the world’s first AI-powered voice analytics system to detect drug and alcohol impairment in real time, initially targeting the South American mining sector, where heavy machinery and remote operations make safety monitoring critical. Such advanced screening technology has relevance to a global market spanning a range of safety-sensitive industries, including…

FridayApr 10, 2026 10:00 am

Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA

The immune system is capable of identifying and attacking cancer cells in the body. This process depends on the tumor producing damaged RNA, which then sticks to cell surfaces and provides the antigens that the body identifies as foreign and therefore targets. However, a natural mechanism within the body that removes faulty RNA ironically aids many cancers to avoid detection and therefore limit immune system responses to the disease. Now, a new preclinical study has found that targeting and blocking this clean-up mechanism can allow cancer antigens to express on tumor cells and allow the immune system to quickly identify and attack them. The study was conducted by a University…

FridayApr 10, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

New AI Tool Could Boost the Early Detection of Lung Cancer

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

Preclinical Study Reveals Promising Treatment for Glioblastoma

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World’s First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search